Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, L.sup.1, L.sup.2, L.sup.3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Compounds having a structure of Formula I:

##STR00001##

or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, L.sup.1, L.sup.2, L.sup.3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

The invention relates to terpenes and uses thereof. ##STR00001##

The invention relates to terpenes and uses thereof. ##STR00001##

The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc.sub.1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbial infections, including fungal infections.

The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc.sub.1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbial infections, including fungal infections.

The present disclosure is drawn to methods of treating diseases or disorders, and uses of preparing medicaments. The methods of administering and/or preparation of medicaments can include the use of a compound of Formula (I) disclosed herein, or a geometric isomer, stereoisomer, and/or pharmaceutically acceptable salt or solvate thereof.

A liquid crystal composition without requiring an alignment film or alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound capable of homogeneously aligning a liquid crystal medium relative to the substrate, for example, a low molecular weight polar compound represented by formula (1):
M-P(1) In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.

A liquid crystal composition without requiring an alignment film or alignment treatment on a substrate. The problem is solved by a low molecular weight polar compound capable of homogeneously aligning a liquid crystal medium relative to the substrate, for example, a low molecular weight polar compound represented by formula (1):
M-P(1) In formula (1), M is a nonpolar group having 1 or more carbons, and P is a polar group.

The invention provides compounds for use in inhibiting a microbial alternative oxidase (AOX) and/or cytochrome bc.sub.1 complex. The invention extends to the use of such inhibitors in agrochemicals and in pharmaceuticals, for treating microbial infections, including fungal infections.